Concepedia

Publication | Open Access

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

DOIFull Paper Access

841

Citations

30

References

2016

Year

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, D-W Kim, Surapol Issaragrisil, Philipp D. le Coutre, Gabriel Étienne, P.E. Dorlhiac‐Llacer, Richard E. Clark,
Leukemia

References

YearCitations

Page 1